category: biolink:CellularComponent biolink:AnatomicalEntity biolink:PhysicalEssence biolink:OrganismalEntity biolink:SubjectOfInvestigation biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: The region between the inner and outer lipid bilayers of the longitudinal sarcoplasmic reticulum envelope. The longitudinal sarcoplasmic reticulum lumen is continuous with the lumen contained within the terminal cisternae.


Conjugate base of bhos#28


pyranoxanthones

Any organic heterotetracyclic compound that consists of a pyran ring fused onto a xanthone skeleton.


COCHINENSOXANTHONE

A member of the class of pyranoxanthones that is 3,4-dihydro-2H,12H-pyrano[2,3-a]xanthen-12-one substituted by hydroxy groups at positions 3, 5 and 10, geminal methyl groups at position 2 and a (2E)-3,7-dimethylocta-2,6-dien-1-yl group at position 6. It has been isolated from the stems of Cratoxylum cochinchinense.


jacarelhyperol B

A member of the class of pyranoxanthones isolated from Hypericum japonicum. It has been found to exhibit inhibitory activity against platelet-activating factor (PAF)-induced hypertension.


brasixanthone D

A member of the class of pyranoxanthones that is 2H,6H-pyrano[3,2-b]xanthen-6-one substituted by a 2-[(2S)-3,3-dimethyloxiran-2-yl]-2-hydroxyethyl group at position 12, hydroxy groups at positions 5 and 8 and geminal methyl groups at position 2. It is isolated from the stem bark of Calophyllum brasiliense and exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation in Raji cells.


blancoxanthone

A member of the class of pyranoxanthones that is  2H,6H-pyrano[3,2-b]xanthen-6-one substituted by hydroxy groups at positions 5 and 10, geminal methyl groups at position 2 and a 2-methylbut-3-en-2-yl group at position 12. It is isolated from the roots of Calophyllum blancoi and exhibits antiviral activity against coronavirus.


brasixanthone B

A member of the class of pyranoxanthones that is 2H,6H-pyrano[3,2-b]xanthen-6-one substituted by hydroxy, geminal methyl and a prenyl group at positions 5, 8, 2 and 12 respectively. It is isolated from the stem bark of Calophyllum brasiliense and exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation in Raji cells.


A member of the class of  pyranoxanthones that is 2H,6H-pyrano[3,2-b]xanthen-6-one substituted by hydroxy groups at positions 5, 8 and 9, geminal methyl groups at position 2 and a prenyl group at position 12. Isolated from Garcinia lancilimba, it exhibits inhibitory effects on human cancer cell line.


brasixanthone C

A member of the class of pyranoxanthones that is 2H,6H-pyrano[3,2-b]xanthen-6-one substituted by a 2-hydroperoxy-3-methylbut-3-en-1-yl moiety at position 12, hydroxy groups at positions 5 and 8 and geminal methyl groups at position 2. It is isolated from the stem bark of Calophyllum brasiliense and exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation in Raji cells.


yahyaxanthone

A member of the class of pyranoxanthones that is 3H,7H-pyrano[2,3-c]xanthen-7-one substituted by a hydroxy group at position 6, methoxy groups at positions 5, 8, 10 and 11 and geminal methyl groups at position 3. Isolated from Garcinia rigida, it exhibits cytotoxic activity.


A member of the class of  pyranoxanthones that is 3H,7H-pyrano[2,3-c]xanthen-7-one substituted by hydroxy groups at positions 6, 10 and 11, geminal methyl groups at position 3 and a prenyl group at position 5. Isolated from Garcinia lancilimba, it exhibits inhibitory effects on human cancer cell line.


jacarelhyperol A

A member of the class of  pyranoxanthones isolated from Hypericum japonicum. It has been found to exhibit inhibitory activity against platelet-activating factor (PAF)-induced hypertension.


A serine derivative resulting from the formal condensation of the carboxy group of 2,3-dihydroxybenzoic acid with the amino group of serine.


puromycin

An aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium, that causes premature chain termination during translation taking place in the ribosome.


O-demethylpuromycin

A derivative of puromycin lacking the O-methyl group on the tyrosyl residue.


Recurrent Childhood Optic Nerve Glioma

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: The reemergence of optic nerve glioma in childhood after a period of remission.


Childhood Intracranial Neoplasm

description: A neoplasm that arises within the skull and occurs during childhood.


name: Recurrent Childhood Visual Pathway Glioma

description: The reemergence of visual pathway glioma in childhood after a period of remission.


name: Childhood Supratentorial Ependymoma ZFTA Fusion-Positive

description: A supratentorial ependymoma ZFTA fusion-positive that occurs during childhood.


Childhood Supratentorial Neoplasm

description: A neoplasm that affects the supratentorial region of the brain and occurs during childhood.


Childhood Benign Brain Neoplasm

description: A childhood neoplasm that arises from the brain and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


Refractory Childhood Brain Neoplasm

description: A childhood brain neoplasm that is resistant to treatment.


name: Childhood Atypical Choroid Plexus Papilloma

description: An atypical choroid plexus papilloma that occurs during childhood.


name: Childhood Pineal Parenchymal Cell Neoplasm

description: A pineal parenchymal cell neoplasm that occurs during childhood.


name: Childhood Subependymal Giant Cell Astrocytoma

description: Subependymal giant cell astrocytoma that occurs during childhood.


Childhood Gliomatosis Cerebri

description: Gliomatosis cerebri that occurs during childhood.


name: Supratentorial Ependymoma, YAP1-MAMLD1 Fusion-Positive

description: A supratentorial ependymoma characterized by a gene fusion involving YAP1 and MAMLD1 genes.


name: Metastatic Childhood Malignant Brain Neoplasm

description: A childhood malignant neoplasm that arises from the brain and has spread from its original site of growth to other anatomic sites.


name: Childhood Dysembryoplastic Neuroepithelial Tumor

description: A dysembryoplastic neuroepithelial tumor that occurs during childhood.


Recurrent Childhood Gliomatosis Cerebri

description: The reemergence of gliomatosis cerebri in childhood after a period of remission.


Recurrent Childhood Brain Neoplasm

description: The reemergence of brain neoplasm in childhood after a period of remission.


name: Childhood Pineal Parenchymal Tumor of Intermediate Differentiation

description: A pineal parenchymal tumor of intermediate differentiation that occurs during childhood.


name: Childhood Diffuse Midline Glioma, H3 K27-Altered

description: A diffuse midline glioma, H3 K27-altered that occurs during childhood.


name: Childhood Cerebral Ependymoma, Not Otherwise Specified

description: An ependymoma, not otherwise specified that arises from the cerebral hemispheres and occurs during childhood.


Childhood Brain Anaplastic Astrocytoma

description: An anaplastic astrocytoma that arises from the brain and occurs during childhood.


Childhood Brain Oligodendroglioma

description: An oligodendroglioma that arises from the brain and occurs during childhood.


Childhood Brain Glioblastoma

description: A brain glioblastoma that occurs during childhood.


Childhood Malignant Brain Neoplasm

description: A primary or metastatic malignant neoplasm affecting the brain during childhood.


name: Metastatic Childhood Malignant Neoplasm in the Brain

description: A childhood malignant neoplasm that has spread from its original site of growth to the brain.


Childhood Brain Neoplasm

description: A benign or malignant, primary or metastatic neoplasm of the brain occurring in children.


name: Childhood Benign Supratentorial Neoplasm

description: A childhood neoplasm that arises from the supratentorial region and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


name: Childhood Multinodular and Vacuolated Neuronal Tumor

description: A multinodular and vacuolated neuronal tumor that occurs during childhood.


Childhood Cerebral Diffuse Astrocytoma

description: A diffuse astrocytoma that arises from the cerebral hemispheres and occurs during childhood.


name: Advanced Childhood Malignant Brain Neoplasm

description: A childhood malignant neoplasm that arises from the brain and has spread extensively to other anatomic sites or is no longer responding to treatment.


Childhood Benign Cerebral Neoplasm

description: A childhood neoplasm that arises from the cerebrum and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


An O-[S-(3R)-3-hydroxyacylpantetheine-4'-phosphoryl]serine(1-) residue in which the S-acyl group is specified as (3R,5Z,17Z)-3-hydroxyhexatriacontadienoyl.


A polysaccharide derivative with a repeating unit consisting of alpha-D-mannosyl, alpha-L-rhamnosyl and alpha-D-galactosyl residues linked sequentially (1->4) and (1->3), to the mannosyl residue is linked (1->3) an alpha-tivelosyl residue, while to the galactosyl residue is linked (1->4) or (1->6) an alpha-D-glucosyl residue, with all repeating units being linked (1->2). O-polysaccharide repeat from Salmonella Enteritidis (serogroup D).


segmented neutrophil of bone marrow

category: biolink:Cell biolink:AnatomicalEntity biolink:PhysicalEssence biolink:OrganismalEntity biolink:SubjectOfInvestigation biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: A segmented neutrophilic cell of the bone marrow reserve pool that expresses CD11b (integrin alpha-M) and high levels of CD16 (low affinity immunoglobulin gamma Fc region receptor III) on its cell surface.


A steroid glucosiduronic acid that is 17alpha-estradiol in which the hydroxy hydrogen at position 17 has been replaced by a beta-D-glucuronyl residue.


A member of the class of 2-pyranones that is 2H-pyran-2-one which has been substituted at positions 4 and 6 by hydroxy and pyridin-3-yl groups, respectively.


An O-(S-acylpantetheine-4'-phosphoryl)serine(1-) residue in which the S-acyl group is specified as (3R)-hydroxybutanoyl.


An O-(S-2-carboxyacylpantetheine-4'-phosphoryl)-L-serine(2-) residue in which the S-acyl group is specified as 2-carboxydodecanoyl.


kweichowenol B

A benzoate ester that is the diester obtained by the formal condensation of two molecules of benzoic acid with the hydroxymethyl group at position 1 and the hydroxy group at position 4 of 1-(hydroxymethyl)cyclohex-5-ene-1,2,3,4-tetrol the (1S,4R,5S,6S stereoisomer). Isolated from the leaves of Uvaria kweichowensis, it exhibits antitumour activity.


poly(vinyl fluoride)

A polymer composed of repeating fluoroethyl units.


ALLITRIDIN

An organic trisulfide that is trisulfane in which both of the hydrogens are replaced by allyl groups. A component of the essential oil of garlic and a major component of the traditional Chinese medicine allitridium, it exhibits antifungal, antitumour and antioxidant activity


(S)-salsolinol

A 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol that has S-configuration.


Retropharyngeal Neoplasm

description: A benign or malignant neoplasm that affects the retropharyngeal space.


Malignant Retropharyngeal Neoplasm

description: A primary or metastatic malignant neoplasm that affects the retropharyngeal space.


Benign Retropharyngeal Neoplasm

description: A neoplasm that arises from the retropharyngeal space and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


carborane

A class of boron compound of general formula [(CH)a(BH)mHb](c)  where c can be positive, negative or zero. The CH groups occupy polyhedron vertices, and other hydrogen atoms are either bridging or terminal.


name: Group B Streptococcal Infection, Late-Onset

description: Infection of an infant from seven days to three months of life caused by Group B Streptococcus (Streptococcus agalactiae).


name: Group B Streptococcal Infection, Early-Onset

description: Infection of an infant from birth to less than seven days of life caused by Group B Streptococcus (Streptococcus agalactiae) from a colonized mother.


beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc in which the configuration of the anomeric centre of the reducing-end N-acetylglucosamine residue is beta.


A trans,trans-2,3,4,5-tetradehydroacyl-CoA having trans,trans-octa-2,4-dienoyl as the S-acyl component.


A trans,trans-2,3,4,5-tetradehydroacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans,trans-2,4-hexadienoic acid.


A trans,trans-2,3,4,5-tetradehydroacyl-CoA having trans,trans-deca-2,4-dienoyl as the S-acyl component.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 2.


dodecanediol

A diol that is dodecane carrying two hydroxy groups at unspecified positions.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 8.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 9.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 5.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 6.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 3.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 10.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 7.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 12.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 4.


name: Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


Umbilical hernia with gangrene

description: A protrusion of necrotic tissue through the abdominal wall under the skin near the umbilicus.


syringaldehyde acetate

A phenyl acetate obtained by the formal condensation of the hydroxy group of syringaldehyde with acetic acid.


N-methyl-L-methionine

A methyl-L-methionine having the methyl group attached to the alpha-amino function.


Cerebral abscess

description: A bacterial, fungal, or parasitic abscess that develops in the cerebral hemispheres. Causes include skull trauma, middle ear infection, congenital heart disease, and frontal and ethmoid sinus infection.


Epithelioid schwannoma

description: A schwannoma characterized by the presence of epithelioid cells with eosinophilic cytoplasm, within a myxoid and/or hyalinized stroma.


cardenolide

A steroid lactone that is a C23 steroid with methyl groups at C-10 and C-13 and a butenolide ring at C-17.


digoxigenin monodigitoxoside

A steroid saponin that consists of digoxigenin having a digitoxosyl residue attached at position 3.


gitoxin

A cardenolide glycoside that is gitoxigenin in which the 3beta-hydroxy group has been glycosylated with tridigitoxose.


A cardenolide glycoside that is the 16-acetate of gitoxin.


oleandrin

A steroid saponin that consists of oleandrigenin having a 2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl residue attached to the oxygen function at position 3.


deslanoside

A cardenolide glycoside that is lanatoside C with the acetoxy group replaced by a hydroxy group.


ELAEODENDROSIDE V

A cardenolide glycoside that is sarmentologenin glycosylated at position 3 by a beta-allosyl-(1->4)-beta-6-deoxyallosyl moiety. Isolated from Elaeodendron alluaudianum, it exhibits antiproliferative activity against human ovarian cancer and human histiocytic lymphoma cell lines.


A cardenolide glycoside that is the 7,8-dehydroderivative of cerberin. Isolated from Cerbera manghas, it exhibits cytotoxic activity.


tanghinin

A  cardenolide glycoside that is  tanghinigenin attached to a 2-O-acetyl-6-deoxy-3-O-methyl-alpha-L-glucopyranosyl residue at position 3 via a glycosidc linkage. Isolated from Cerbera manghas, it exhibits cytotoxic activities against oral human epidermoid carcinoma (KB), human breast cancer cell (BC) and human small cells lung cancer.


cardenolide glycoside

Any member of the class of cardenolides with glycosyl residues attached to position 3.


acetyldigitoxin

A cardenolide glycoside compound consisting of digitoxin having an acetyl substituent at the 3-position on the D-ribo-hexopyranosyl residue at the non-reducing end.


digitoxin

A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.


acovenoside A

A cardenolide glycoside that is the 3-(6-deoxy-3-O-methyl-alpha-L-taloside) of 1beta,3beta,14-trihydroxy-5beta-card-20(22)-enolide.


GITALOXIN

A cardenolide glycoside that is gitoxin in which the 16beta-hydroxy group has been formylated.


evomonoside

A cardenolide glycoside consisting of digitoxigenin having an alpha-L-rhamnosyl moiety attached at the O(3)-position.


dihydroouabain

A cardenolide glycoside that is ouabain in which the double bond in the lactone ring has been reduced to a single bond. It is a cardiac glycoside and a derivative of ouabain which is used as a sodium pump antagonist and exhibits ionotropic effects.


oleandrigenin monodigitoxoside

A steroid saponin that consists of oleandrigenin having a digitoxosyl residue attached at position 3.


cerberin

A cardenolide glycoside that is the 2'-acetyl derivative of neriifolin.


tanghinigenin

A member of the class of  cardenolides that is 7,8-epoxycard-20(22)-enolide substituted by hydroxy groups at positions 3 and 14 (the 3beta,5beta,7beta stereoisomer).


deacetyltanghinin

A  cardenolide glycoside that is the deacetyl derivative of tanghinin. Isolated from Cerbera manghas, it exhibits cytotoxic activities against oral human epidermoid carcinoma (KB), human breast cancer cell (BC) and human small cells lung cancer.


A cardenolide glycoside that is the 12-acetate of digoxin.


NERIIFOLIN

A cardenolide glycoside that is digitoxigenin in which the hydroxy goup at position 3 has been converted to its (6-deoxy-3-O-methyl-alpha-L-glucopyranoside derivative. Found in the seeds of Cerbera odollamand in Thevetia ahouia and Thevitia neriifolia.


A cardenolide glycoside consisting of digitoxigenin having a beta-D-glucopyrananosyl-(1->4)-alpha-L-acofriopyranosyl moiety attached at the 3-position.


strospeside

A cardenolide glycoside in which the parent structure gitoxigenin is glycosylated at the 3beta-hydroxy group by beta-D-digitalose.


ELAEODENDROSIDE U

A cardenolide glycoside that is carda-4,20(22)-dienolide substituted by hydroxy groups at positions 2 and 14, an oxo group at position 12 and a (4-deoxy-3-O-methyl-alpha-L-erythro-pentopyranosyl)oxy moiety at position 3 (the 2alpha,3beta stereoisomer). Isolated from from wood of Elaeodendron tangenala, it exhibits antiproliferative activity against A2780 human ovarian cancer cells.


SARMENTOGENIN

A member of the class of cardenolides that is 5beta-card-20(22)-enolide which is substituted by hydroxy groups at the 3beta, 11alpha, and 14beta positions.


(S)-proglumide

The (S)-enantiomer of the racemic drug proglumide.


palmityl palmitoleate

A wax ester obtained by the formal condensation of  hexadecan-1-ol with  palmitoleic acid.


N-acetyl-D-penicillamine

An N-acetyl-D-amino acid where the amino acid is D-penicillamine


flurbiprofen

A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.


A 3beta-hydroxy steroid that is ecdysone in which the hydroxy group at position 25 is replaced by a hydrogen.


tyclopyrazoflor

A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 4 by a pyridin-3-yl group, chloro group and an ethyl{3-[(3,3,3-trifluoropropyl)sulfanyl]propanoyl}nitrilo group, respectively. It is an insecticide from Dow AgroSciences LLC.


kaempferol 3-O-alpha-L-glucopyranoside

A kaempferol O-glucoside that is  kaempferol attached to an alpha-L-glucopyranosyl moiety at position 3 via a glycosidic linkage.


name: Adult Diffuse Midline Glioma, H3 K27-Altered

description: A rare diffuse midline glioma, H3 K27-altered that occurs during adulthood.


name: Metastatic Adult Malignant Neoplasm in the Brain

description: A malignant neoplasm that has spread from its original site of growth to the brain in an adult patient.


Adult Brain Glioblastoma

description: A brain glioblastoma that occurs during adulthood.


name: COPI-coated Golgi to ER transport vesicle

description: A vesicle that mediates transport from the Golgi to the endoplasmic reticulum.


Recurrent WHO Grade 4 Glioma

description: The reemergence of WHO grade 4 glioma after a period of remission.


name: Recurrent Diffuse Midline Glioma, H3 K27M-Mutant

description: The reemergence of diffuse midline glioma, H3 K27M mutant, after a period of remission.


An amino tetrasaccharide consisting of a 6-O-[(2-aminoethoxy)(hydroxy)phosphoryl-alpha-D-mannopyranosyl residue, two alpha-D-mannopyranosyl residues, and a 2-amino-alpha-D-glucose residue linked together in sequence by (1->2), (1->6) and (1->4) glycosidic bonds.


name: Congenital anomaly of the urinary tract proper

description: An abnormality of the kidney, ureter, bladder, or urethra that is present at birth. Representative examples include renal hypoplasia, renal agenesis, accessory kidney, absence of ureter, atresia of bladder neck, and atresia of urethra.


Urachal remnant

description: Remaining collapsed and obliterated urachal tissue between the bladder dome and umbilicus.


Posterior Urethral Valves Type 1

description: A posterior urethral valve extending from the vera montanum towards the distal meatus.


Posterior Urethral Valves Type 3

description: A posterior urethral valve, presumed to result from incomplete canalization of the urethra, that is located immediately distal to the vera montanum.


Double kidney (disorder)

description: A congenital abnormality of the kidney characterized by the presence of two separate pelvicocaliceal systems with a single or duplex ureter.


Congenital Renal Hypoplasia

description: The underdevelopment of otherwise normal renal parenchyma, characterized by decreased nephron size and possibly a decreased number of nephrons at birth.


Prostatic Duct Urothelial Carcinoma

description: An urothelial carcinoma that arises from the urothelial lining of the prostatic ducts.


poly(3,6-carbazole) macromolecule

A macromolecule composed of repeating 3,6-linked substituted or unsubstituted carbazole units.


poly(carbazole-3,6-diyl) macromolecule

A macromolecule composed of repeating 3,6-linked carbazole units.


name: Ann Arbor Stage II Supradiaphragmatic Lymphocyte-Depleted Classic Hodgkin Lymphoma


inorganic selenium salt

A selenium salt that lacks C-H bonds


name: large cell neuroendocrine carcinoma of kidney

description: An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the kidney.  It is characterized by the presence of malignant large cells.


name: 4,5-dichloro-3-isothiazolecarboxylic acid [1-oxo-1-(thiophen-2-ylmethylamino)butan-2-yl] ester


An N,N-disubstituted toluene-p-sulfonamaide, with a structure close to that of darunavir. It is found to inhibit dimerization of HIV-1 protease subunits.


A cholestanoid that is cholestanol which is substituted by a hydroxy group at position 26 and has R-configuration at position 25.


name: Squamous cell carcinoma of the oral cavity stage I

description: Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage I includes: T1, N0, M0. T1: Tumor 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


3-hydroxyisobutyric acid

A 4-carbon, branched hydroxy fatty acid and intermediate in the metabolism of valine.


The 5alpha-stereoisomer of  4,5-dihydrocortisone.


cefpiramide

A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a broad spectrum of antibacterial activity.


N-arachidonoylserotonin

An N-acylserotonin obtained by formal condensation of the carboxy group of arachidonic acid with the primary amino group of serotonin.


N-acylserotonin

A fatty amide resulting from the condensation of the carboxy group of a fatty acid with the primary amino group of serotonin.


N-butanoylserotonin

An N-acylserotonin obtained by formal condensation of the carboxy group of butyric acid with the primary amino group of serotonin.


N-oleoylserotonin

An N-acylserotonin obtained by formal condensation of the carboxy group of oleoic acid with the primary amino group of serotonin.


N-stearoylserotonin

An N-acylserotonin obtained by formal condensation of the carboxy group of stearic acid with the primary amino group of serotonin. It has been found in the jejunum and ileum of pigs and mice.


N-palmitoylserotonin

An N-acylserotonin obtained by formal condensation of the carboxy group of hexadecanoic acid with the primary amino group of serotonin.


carbapenem MM22383

A carbapenemcarboxylic acid having a 2-(acetamidovinyl)sulfanyl group at the 2-position and an (S)-1-hydroxyethyl group at the 6-position.


(2R)-hydroperoxy fatty acid

Any 2-hydroperoxy fatty acid which has R configuration at the carbon bearing the hydroperoxy group.


(R)-2-hydroperoxy-alpha-linolenic acid

A hydroperoxy fatty acid that is alpha-linolenic acid having a single hydroperoxy substituent located at the 2R-position.


sonolisib

An organic heterotetracyclic compound that is obtained from wortmanin via aminolysis of its furan ring by diallyl amine.


(S)-3-amino-3-phenylpropanoic acid

An optically active form of 3-amino-3-phenylpropanoic acid having S-configuration.


5'-end NAD(1-) residue

An organic anionic group obtained by deprotonation of the phosphate OH groups of a   5'-end NAD(+) CAP residue; major species at pH 7.3.


Childhood Bone Osteosarcoma

description: An osteosarcoma that arises from the bone and occurs during childhood.


Refractory Childhood Osteosarcoma

description: Childhood osteosarcoma that is resistant to treatment.


ansaetherone

An eleven-membered macrocyclic lactam that consists of (2S,3E,5Z,14S,15R)-5-ethylidene-11,14-dihydroxy-3,7,15-trimethyl-2,5-dihydro-2,13-ethano-1,9-benzoxazacycloundecine-6,8-dione in which the 14-hydroxy group is substituted by a (2R,5R,6R)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl moiety. It is a radical scavenger isolated from Streptomyces.


(R)-thalidomide

A 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione that has R-configuration at the chiral centre.


A heteroacene compound consisting of benzothiophene fused to anthracene in a rectilinear arrangement.


heteroacene

An acene composed of heteroatom-substituted aromatic groups.


An organic cation that is 1,2,4,6-tetraoxohexahydropyrimidin-1-ium substituted by a cyclohex-1-en-1-yl group at position 5 and methyl groups at positions 3 and 5.


pyroglutamylglutamine

A dpeptide obtained by formal condensation of the carboxy group of L-pyroglutamine with the amino group of L-glutamine


name: Benign Extrahepatic Bile Duct Non-Epithelial Neoplasm

description: A neoplasm that arises from the non-epithelial tissues of the extrahepatic bile ducts and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


Extrahepatic Bile Duct Fibroma

description: A benign neoplasm arising from the extra hepatic bile duct. It is characterized by the presence of spindle-shaped fibroblasts.


name: Benign Extrahepatic Bile Duct Soft Tissue Neoplasm

description: A mesenchymal neoplasm that arises from the extrahepatic bile ducts and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


name: Extrahepatic Bile Duct Benign Granular Cell Tumor

description: A granular cell tumor that arises from the extrahepatic bile ducts and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


An organic group derived from alpha-D-GlcpNAc-(1->3)-[P-6-[CH2]5NH2]-alpha-D-GlcpNAc-(1->2)-D-GroA (CHEBI:134201) in which the 5-aminopentyl linker is replaced by a 6-(pentylamino)hexanamido one. When linked to the diphtheria toxin mutant 197CRM, it shows potential as a Clostridium difficile vaccine candidate.


Aflatoxin B1 endo-cysteinyl-conjugate

A metabolite of aflatoxin B1


Pigmented epithelioid melanocytoma

description: A rare cutaneous melanocytic neoplasm that presents as a slow growing pigmented nodule or papule. It is characterized by the proliferation of heavily pigmented epithelioid and dendritic cells, predominantly in the dermis. PRKAR1A gene inactivation is present in the majority of cases. It can spread to regional lymph nodes, but distant metastases are rare.


name: 4-chlorobenzoic acid (5-methyl-2-pyridin-4-yl-4-thiazolyl) ester


inorganic antimony salt

A antimony salt that lacks C-H bonds


steffimycin D

An anthracycline antibiotic that is steffimycin in which the carbonyl group that is adjacent to the carbon bearing both a hydroxy group and a methyl group has been reduced to the corresponding methylene group. An antitumour anthracycline first isolated from Streptomyces steffisburgensis.


(S)-4-amino-5-oxopentanoic acid

A 5-oxo monocarboxylic acid that is 5-oxopentanoic acid substituted by an amino group at position 4 (the 4S-stereoisomer).


Unresectable Pilocytic Astrocytoma

description: A pilocytic astrocytoma that is not amenable to surgical resection.


Unresectable Astrocytic Tumor

description: An astrocytic tumor that is not amenable to surgical resection.


Unresectable Glioblastoma

description: A glioblastoma that is not amenable to surgical resection.


Unresectable Astrocytoma, IDH-Mutant

description: Astrocytoma, IDH-mutant that is not amenable to surgical resection.


An androstanoid with a 5beta-configuration formed by reduction across the C4-C5 double bond of epitestosterone.


A member of the class of hydroxyindoles that is indoxyl carrying an additional bromo substituent at position 5.


hydroxyindoles

Any member of the class of  indoles carrying at least one hydroxy group.


An N-acyl-amino acid obtained by formal condensation of the carboxy group of 6-hydroxyindole-3-acetic acid with the amino group of phenylalanine.


VIOLACEIN

A member of the class of hydroxyindoles resulting from the formal oxidative coupling between the 3-position of 1,3-dihydro-2H-indol-2-one and the 3-position of 1,3-dihydro-2H-pyrrol-2-one, which is substituted at the 5 position by a 5-hydroxy-1H-indol-3-yl group, where the newly-formed double bond has E configuration. It is a purple chromobacterial pigment that has antibacterial, antifungal, antiprotozoan, and anticancer properties.


deoxyviolaceinic acid

A pyrrolecarboxylic acid that is pyrrole-2-carboxylic acid which is substituted at position 3 by a 3-hydroxyindol-3-yl group at at position 5 by an indol-3-yl group.


violaceinic acid

A pyrrolecarboxylic acid that is pyrrole-2-carboxylic acid which is substituted at position 3 by a 3-hydroxyindol-3-yl group at at position 5 by a 5-hydroxyindol-3-yl group.


dopaminechrome (enol form)

A member of the class of indolones that is 3,5-dihydro-2H-indole substituted by an oxo group at position 5 and a hydroxy group at position 6.


indoxyl

A member of the class of hydroxyindoles that is 1H-indole substituted by a hydroxy group at position 3.


2-hydroxy-(indol-3-yl)acetic acid

A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the hydrogen at position 2 has been replaced by a hydroxy group. This is a very minor tautomer; the major tautomer is the corresponding oxindole.


Major microspecies at pH 7.3


proviolacein

A hydroxyindole that is 2H-pyrrol-2-one which is substituted at positions 3 and 5 by 1H-indol-3-yl and 5-hydroxy-1H-indol-3-yl groups, respectively. It is an intermediate in the biosynthesis of the purple chromobacterial pigment violacein from L-tryptophan.


A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.


An oxindole that is 1,3-dihydro-2H-indol-2-one substituted by a hydroxy group at position 3.


notoamide S

A notoamide that is 2-(2-methylbut-3-en-2-yl)-7-(3-methylbut-2-en-1-yl)-1H-indol-6-ol which has been substituted at position 3 by a [(3S,8aS)-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl]methyl group.  Isolated from a mussel-derived Aspergillus species. The precursor of notoamide E.


A heteroarenecarbaldehyde that is 4-hydroxyindole in which the hydrogen at position 3 has been replaced by a formyl group.


A methylindole that is 1,3-dihydro-2H-indol-2-one substituted by methyl and a hydroxy group at position 3.


A member of the class of hydroxyindoles that is indoxyl carrying additional chloro and bromo substituents at positions 4 and 5 respectively.


N-acetylindoxyl

A hydroxyindole that is indoxyl in which the hydrogen attached to the nitrogen is replaced by an acetyl group.


psilocin

A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional hydroxy substituent at position 4. A hallucinogenic alkaloid isolated in trace amounts from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms").


An N-acylglycine resulting from the formal condensation of the carboxy group of (5-hydroxyindol-3-yl)acetic acid with the amino group of glycine.


5,6-dihydroxyindole-2-carboxylic acid

A dihydroxyindole that is indole-2-carboxylic acid substituted by hydroxy groups at positions 5 and 6.


protoviolaceinic acid

A pyrrolecarboxylic acid that is pyrrole-2-carboxylic acid which is substituted at position 3 by a 1H-indol-3-yl group at at position 5 by a 5-hydroxy-1H-indol-3-yl group.


A member of the class of hydroxyindoles that is melatonin in which the hydrogen at position 2 of the indole ring has been replaced by a hydroxy group. A predominant hydroxylated melatonin metabolite in plants.


A member of the class of  hydroxyindoles that is 1H-indole substituted by a hydroxy group at position 4.


3-(5-hydroxyindol-3-yl)pyruvic acid

A hydroxyindole that is indole substituted by a 2-carboxy-2-oxoethyl group at position 2 and a hydroxy group at position 5.


A fatty amide obtained by formal condensation of the carboxy group of arachidonic acid with the amino group of 2-oxoserotonin.


A member of the class of tryptamines that is tryptamine in which the the indole ring has been substituted by a hydroxy group at position 4.


4-hydroxy-indole-3-carbonyl nitrile

A member of the class of hydroxyindoles that is 1H-indol-4-ol which is substituted by a nitriloacetyl group at the 3 position.


N-FERULOYL SEROTONIN

A member of the class of hydroxyindoles that is the N-feruloyl derivative of serotonin.


A member of the class of hydroxyindoles that is 1H-indole substituted by hydroxy, 5-(morpholin-4-ylmethyl)pyridin-2-yl, and cyano groups at positions 2, 3 and 5, respectively. It is a potent, brain permeable inhibitor of human GSK3alpha and GSK3beta with Ki of 6.9 nM and 31 nM, respectively. The drug was being developed by AstraZeneca for the treatment of Alzheimer's disease (clinical trial now discontinued).


A member of the class of hydroxyindoles that is 1H-indole in which the hydrogen at position 5 has been replaced by a hydroxy group.


BROMOTOPSENTIN

An aromatic ketone that is imidazole that is substituted at positions 2 and 5 by (6-hydroxy-1H-indol-3-yl)carbonyl and 6-bromo-1H-indol-3-yl groups respectively. Isolated from Mediterranean shallow-water sponges Topsentia genetrix, and from Caribbean deep-sea sponges of the Halichondriidae family, it has antitumour and antiviral properties. Toxic to fish.


A ceramide obtained by formal condensation of the carboxy group of tetracosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.


name: follicular dendritic cell sarcoma of thyroid gland

description: A rare follicular dendritic cell sarcoma involving the thyroid gland. It may be associated with chronic lymphocytic thyroiditis.


Acquired hallux valgus

description: A non-congenital deformity characterized by lateral deviation of the great toe.


zeta-cypermethrin

A diastereoisomeric mixture comprising the isomeric pair (1R)-cis-(alphaS)- and (1S)-trans-(alphaR)-cypermethrin together with the isomeric pair (1S)-cis-(alphaS)- and (1S)-trans-(alphaS)-cypermethrin where the ratio between the isomeric pairs lies in the range 45:55 to 55:45.


Moderate Bronchopulmonary Dysplasia

description: A chronic lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates exposed to supplemental oxygen for at least 28 days. For infants born before 32 weeks gestation with moderate BPD, there is a supplemental oxygen requirement of less than 30% at 36 weeks postmenstrual age or earlier discharge. For infants born after 32 weeks with moderate BPD, there is a supplemental oxygen requirement of less than 30% at 56 days post-natal age or at earlier discharge.


glycopolymer

A polymer, composed of glycopolymer macromolecules.


A random copolymer based on poly-L-lysine containing a disaccharide glycomimetic of the natural HNK-1 (human natural killer-1) glycoepitope. The proportions of the HNK-1 glycomimetic-modified poly-L-lysine component and the unmodified poly-L-lysine component (labelled m and m respectively in the diagram) are respectively x% and (100-x)%.


name: O-alpha-D-glucosyl poly(glycerol phosphate) polymer

description: A glycopolymer, composed of O-alpha-D-glucosyl poly(glycerol phosphate) macrmolecules.


A glycopolymer composed of a poly(glycerol phosphate) backbone which is randomly glycosylated by alpha-D-glucosyl residues at the secondary hydroxy positions.


A linear trisaccharide galactosaminyl group consisting of alpha-L-fucosyl, beta-D-galactosyl and N-acetyl-beta-D-D-galactosaminyl residues linked sequentially (1->2) and (1->3). Blood group type-IV H determinant.


viral factory

description: An intracellular compartment in a host cell which increases the efficiency of viral replication, and shields the virus from host defenses. Viral factories can be either cytoplasmic or nuclear and often arise from extensive rearrangement of host cell cytoskeletal and/or cell membrane compartments.


cytoplasmic viral factory

description: A viral factory located in the cytoplasm of a host cell.


Kidney Lymphangioma

description: A rare lymphangioma arising from the kidney.


A branched ten-residue glucosaminyl group consisting of a linear sequence of two D-mannosyl and two N-acetyl-D-glucosaminyl residues linked sequentially alpha(1->3), beta(1->4) and beta(1->4), to the mannosyl residue at the non-reducing end of which are linked beta(1->2) and beta(1->4) two N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl linear trisaccharide units.


Prostate Hemangioma

description: A rare hemangioma that arises from the prostate gland.


salicylaldehyde N-tosylimine

Salicylaldehyde imine with a tosyl (toluene-p-sulfonyl) group bonded to the imine N atom.


Vulvar Congenital Melanocytic Nevus

description: A benign nevus that arises from the vulva and is present at birth.


Congenital small melanocytic nevus

description: A congenital melanocytic nevus of small size, with a diameter smaller than 15 mm. It presents as a macular, papular or plaque-like lesion.


name: Intermediate Congenital Melanocytic Nevus

description: A congenital melanocytic nevus measuring 15-200 mm. It is typically amenable to surgical resection.


name: Proliferative dermal lesion in congenital nevus

description: A benign proliferation of epithelioid or spindled melanocytes usually in the upper or mid dermis in a background of congenital melanocytic nevus. The congenital melanocytic nevus is usually of the deep type, involving the dermis and extending into the subcutaneous tissue. It presents as a dark plaque or nodule above a giant congenital melanocytic nevus.


alpha-D-kanosamine

A 3-amino-3-deoxy-D-glucopyranose that has alpha-configuration at the anomeric position.


WITHALONGOLIDE H

A  withanolide saponin that consists of withaferin A attached to a alpha-L-rhamnopyranosyl(1->4)-beta-D-glucopyranosyl residue via a glycosidic linkage. Isolated from the aerial parts of Physalis longifolia, it exhibits antineoplastic activity.


A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde in which the hydrogens at positions 3 and 6 have been replaced by a methyl and 2-oxopropyl groups, respectively.


xenocyloin

A member of the class of indoles that is 1-H indole with the hydrogen at position 3 substituted with a 2'-hydroxy-3'-alkoxy-4'-alkyl group. It is an antiinsectan compound found in the nematode parasite Xenorhabdus bovienii.


An oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of 3-oxooctanoic acid.


name: Central Nervous System Solitary Fibrous Tumor, Grade 1

description: A solitary fibrous tumor that arises from the central nervous system. It corresponds most often to the collagenous and low cellularity spindle cell tumor which was diagnosed as central nervous system solitary fibrous tumor in the past.


6-carboxyrhodamine 6G

A rhodamine 6G compound having a carboxy substituent in the 6-position.


DIPYRIDYL

A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.


Gly-D-Thr

A dipeptide formed from glycine and D-threonine residues.


3-methoxytyramine sulfate

An aryl sulfate that is 3-methoxytyramine in which the phenolic hydrogen has been replaced by a sulfo group.


A steroid saponin isolated from Ornithogalum thyrsoides and has been shown to exhibit cytotoxic activity.


A 4-(phosphonomethyl)phenylalanine that has D-configuration.


A phenylalanine derivative that is phenylalanine substituted by a phosphonomethyl group at position 4.


A 4-(phosphonomethyl)phenylalanine that has L-configuration.


(E)-5-(2-methylphenyl)-4-pentenoic acid

This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety


Zwitterionic form of N(6)-acetyl-N(6)-hydroxy-L-lysine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3


An omega-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 16-hydroxyhexadecanoic acid.


A beta-D-glucoside that is the 5-aminopentyl glycoside of a tetrasaccharide consisting of beta-D-glucosyl, beta-D-galactosyl, beta-D-glucuronosyl and beta-D-glucosyl residues linked sequentially (1->4).


name: Familial Hemophagocytic Lymphohistiocytosis Type 4

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STX11 gene.


name: Familial Hemophagocytic Lymphohistiocytosis Type 2

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the PRF1 gene.


name: Familial Hemophagocytic Lymphohistiocytosis Type 3

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the UNC13D gene.


description: The reemergence of hemophagocytic lymphohistiocytosis after a period of remission.


description: Hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection.


name: Familial Hemophagocytic Lymphohistiocytosis Type 5

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STXBP2 gene.


description: Hemophagocytic lymphohistiocytosis associated with a viral infection.


Refractory Fungal Infection

description: A fungal infection that is resistant to treatment.


Renal Benign Mesenchymoma

description: A benign mesenchymoma arising from the kidney.


4-oxo-4-(pyridin-3-yl)butanoic acid

A monocarboxylic acid that is succinic acid in which the hydroxy group of one of the carboxy groups is replaced by a pyridin-3-yl group.  A byproduct of tobacco-specific N-nitrosamines generated by cytochrome P-450 which catalyzes methylnitrosaminopyridylbutanone hydroxylation, this nicotine metabolite is commonly found in the urine of smokers.


Mild Bronchopulmonary Dysplasia

description: A chronic lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates exposed to supplemental oxygen for at least 28 days. For infants born before 32 weeks gestation with mild BPD, there is no supplemental oxygen requirement at 36 weeks postmenstrual age or earlier discharge. For infants born after 32 weeks with mild BPD, there is no supplemental oxygen requirement at 56 days post-natal age or at earlier discharge.


H influenze type B Pneumonia

description: Pneumonia that is attributed to the bacteria H influenze type B.


Collapsed Lung

description: Atelectasis of an entire lung.


Community acquired pneumonia

description: Pneumonia that is not acquired in a hospital or long-term care facility setting.


name: Somatoform autonomic dysfunction - respiratory tract

description: A respiratory malfunction for which mental factors play a causative role.


Acute pneumonia

description: Acute inflammation of the lung parenchyma caused by viruses, bacteria, fungi, radiation treatment, or exposure to chemicals.  Signs and symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.


Non-Neoplastic Lung Disorder

description: A lung disorder not caused by a neoplasm. Representative examples include chronic obstructive pulmonary disease, atelectasis, lung infections, pulmonary fibrosis, and pneumoconiosis.


Bronchiolitis Obliterans Syndrome

description: Bronchiolitis obliterans following lung or allogeneic hematopoietic cell transplantation.


Follicular Bronchitis/Bronchiolitis

description: A non-neoplastic disorder characterized by the formation of reactive lymphoid follicles adjacent to distal bronchi and bronchioles.  It presents with mild shortness of breath and is associated with immunodeficiency syndromes and collagen vascular disorders.


COVID-19-Associated Pneumonia

description: Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by the presence of ground glass opacities on CT scan images.


Congenital anomaly of lung

description: A malformation in the lung that is present at birth. Representative examples include pulmonary hypoplasia, pulmonary agenesis, congenital lobar emphysema, and alveolar capillary dysplasia.


Pulmonary alveolitis

description: Inflammation of the alveoli of the lung.


name: Respiratory Failure Related to Neuromuscular Disorder

description: Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a neuromuscular disorder.


Pulmonary cryptococcosis

description: Fungal pneumonia caused by inhalation of particles of Cryptococcus.  It usually occurs in immunocompromised patients such as persons with AIDS, transplant recipients, patients receiving cytotoxic chemotherapy, and patients with hematologic malignancies.  It is rare in immunocompetent individuals.  Signs and symptoms include fever, cough, and dyspnea.


name: Pneumonia caused by respiratory syncytial virus

description: Pneumonia that is attributed to the respiratory syncytial virus.


Hospital acquired pneumonia

description: Pneumonia acquired during a hospital stay.


Paracicatricial Emphysema

description: The development of dilated terminal airspaces in the lung adjacent to parenchymal scarring.


name: Chronic obstructive asthma (with obstructive pulmonary disease)

description: Chronic airway obstruction caused by asthma.


Pulmonary vascular disorder

description: A category of non-neoplastic disorders that affect the blood vessels in the lungs.  Representative examples include pulmonary embolism, pulmonary hypertension, and arteriovenous malformations.


Steroid-Refractory Pneumonitis

description: Pneumonitis that does not respond to corticosteroid therapy.


Tuberculous bronchiectasis

description: Bronchiectasis that develops in patients with a history of pulmonary tuberculosis.  It is usually associated with healed scars but occasionally may be seen in patients with active pulmonary tuberculosis.


Severe acute respiratory infection

description: A respiratory infectious disorder that leads to an acute illness that requires medical attention.


Stannosis

description: A disorder associated with chronic exposure to inhaled tin oxide dust or fumes.


Severe Bronchopulmonary Dysplasia

description: Bronchopulmonary dysplasia that results in severe respiratory complications. The infants with severe symptoms are usually premature, have low birth weight, and the oxygen and ventilation support requirements are increased.


name: Pneumonia caused by methicillin resistant Staphylococcus aureus

description: Pneumonia that is caused by Staphylococcus aureus that is resistant to methicillin treatment.


Cannabinosis

description: A disorder associated with chronic exposure to inhaled dust during the processing of hemp.


Asbestos-Related Lung Disorder

description: A disorder affecting the lungs due to asbestos exposure. Examples include asbestosis and lung carcinoma.


Toxoplasma Pneumonia

description: Pneumonia caused by the parasite Toxoplasma gondii.  It usually presents as an opportunistic infection in immunocompromised patients, especially patients with AIDS.  It is rare in immunocompetent individuals.  Signs and symptoms include cough, fever, and dyspnea.


Secondary Pneumonia

description: A pneumonia that occurs during or following treatment for an acute (primary) pneumonia that was caused by a different organism. It may be the result of increased susceptibility due to the initial treatment.


Pulmonary trunk hypoplasia

description: Underdeveloped pulmonary arteries.


Non-cardiogenic pulmonary edema

description: Pulmonary edema that is not a result of cardiac dysfunction.


name: Respiratory Failure Related to Central Nervous System Disorder

description: Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a central nervous system disorder.


name: Autoimmune Pulmonary Alveolar Proteinosis

description: A type of pulmonary alveolar proteinosis associated with low concentrations of GM-CSF.


Sickle Cell Chronic Lung Disease

description: A pulmonary complication of sickle cell disease characterized by radiographic interstitial abnormalities and impaired pulmonary function. In severe cases, pulmonary hypertension is present.


Atypical pneumonia

description: Historical term that references a form of pneumonia caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella species.


Hyaline Membrane Syndrome

description: A serious disorder affecting newborns, particularly premature infants. It is caused by deficiency of surfactant, resulting in the formation of a membrane in the alveoli lining. This membrane contains fibrin and cellular debris and interferes with respiration. Infants with this disorder develop breathing problems immediately or in a few hours after delivery. It may lead to respiratory failure.


Fibrotic Hypersensitivity Pneumonitis

description: Interstitial lung fibrosis resulting from chronic hypersensitivity pneumonitis.


AIDS-Related Pneumocystis Pneumonia

description: A serious AIDS-related opportunistic infection of the lungs, caused by Pneumocystis jirovecii.  It is one of the most common AIDS-related illnesses and is a major cause of morbidity in patients with AIDS.  Signs and symptoms include cough, fever, dyspnea, and pain or tightness in the chest.


Pulmonary Precancerous Condition

description: A premalignant pathologic process that affects the lungs.  This category includes bronchial intraepithelial neoplasia and atypical adenomatous hyperplasia.


Acute pulmonary edema

description: Rapid or severe onset or rapid progression of pulmonary edema causing significant hypoxemia or the need for supplemental oxygen.


Diffuse Panbronchiolitis

description: A clinico-pathologic syndrome primarily affecting the respiratory bronchioles with evidence of inflammation in all layers of the bronchiole. Sinusitis is often an accompanying feature.


A piperidinecarboxylate ester that is the methyl ester of 3-hydroxypiperidine-1-carboxylic acid.


name: 2-[(2R,3S,6S)-3-amino-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester


diphenidol

A tertiary alcohol that is butan-1-ol substituted by two phenyl groups at position 1 and a piperidin-1-yl group at position 4.


Mesothelial hyperplasia

description: A hyperplasia of the mesothelial cells.


Atypical Mesothelial Hyperplasia

description: An atypical hyperplasia of the mesothelial cells.


poly(1,4-phenylene) macromolecule

A homopolymer macromolecule, composed of sigma-bonded unsubstituted phenyl groups.


Infectious Salpingitis

description: An acute or chronic infectious process affecting the fallopian tube. Chlamydia trachomatis, Neisseria gonorrhea, Mycoplasma, Staphylococcus, and Streptococcus are the most common causative agents.


celabenzine

A cyclic spermidine alkaloid that is 2-phenyl-1,5,9-triazacyclotridecan-4-one in which the amino hydrogen at position 9 has been replaced by a benzoyl group.


cadabicine sulfate

A spermidine alkaloid with formula C25H29N3O7S that is biosynthesised by Arabidopsis thaliana.


celafurine

A cyclic spermidine alkaloid that is 2-phenyl-1,5,9-triazacyclotridecan-4-one in which the amino hydrogen at position 9 has been replaced by a furan-3-carbonyl group.


celacinnine

A spermidine alkaloid that is isolated from Maytenus heterophylla and Maytenus senegalensis.


A beta-D-Glcp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has beta configuration.


A glycosylgalactose consisting of a beta-D-glucopyranose residue and a D-galactopyranose residue joined in sequence by a (1->6) glycosidc bond.


A beta-D-Glcp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has alpha configuration.


Conjunctival Rhabdomyosarcoma

description: A rhabdomyosarcoma that arises from the conjunctiva.


glycycarpan

A member of the class of pterocarpan that is a cis-pterocarpan substituted by a hydroxy group at position 9, a 3-hydroxy-3-methylbutyl group at position 8, a methoxy group at position 1 and a dimethylpyran ring fused across positions 2 and 3. It has been isolated from Glycyrrhiza uralensis.


A peptide cation obtained from the protonation of the N-terminus amino group and L-arginyl side chains, and deprotonation of the C-terminus carboxy group of apelin-12. It is the major species at pH 7.3.


A 15-HETrE consisting of (8Z,11Z,13E)-icosatrienoic acid in which the 15-hydroxy group has S-configuration.


7-demethylmitomycin B

A member of the family of mitomycins that is mitomycin B in which the methoxy group  on the quinone ring is replaced by a hydroxy group.


MITOMYCIN A

A member of the family of mitomycins that exhibits antibiotic and antitumour properties as well as a high level of toxicity.


mitomycin

A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.


7-demethylmitomycin A

A member of the family of mitomycins that is mitomycin A in which the methoxy group on the quinone ring is replaced by a hydroxy group.


MITOMYCIN B

A member of the family of mitomycins that exhibits antibiotic and antitumour properties.


(S)-pydiflumetofen

3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]pyrazole-4-carboxamide that is the (S)-enantiomer of pydiflumetofen.


A 2,3-diacyl-1-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are palmitoyl and oleoyl respectively.


onium betaine

Neutral molecules having charge-separated forms with an onium atom which bears no hydrogen atoms and that is not adjacent to the anionic atom.


An O-acylcarnitine having 13-carboxytridecanoyl as the acyl substituent.


O-arachidonoylcarnitine

An O-acylcarnitine having arachidonoyl as the acyl substituent.


An O-acyl-L-carnitine in which the acyl group specified is 2-hydroxypentanoyl.


An O-acylcarnitine having (2E,4Z)-decadienoyl as the acyl substituent.


O-hydroxyvaleroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is hydroxyvaleroyl in which the position of the hydroxy group is unspecified.


An O-tetradecenoyl-L-carnitine  in which the acyl group is specified as (5Z)-tetradecenoyl.


O-(hydroxyhexadecadienoyl)carnitine

An  O-acylcarnitine having hydroxyhexadecadienoyl as the acyl substituent in which the position of the double bonds and the hydroxy group is unspecified.


O-acryloyl-L-carnitine

An O-acyl-L-carnitine having acryloyl as the acyl group.


O-acetylcarnitine

An O-acylcarnitine having acetyl as the acyl substituent.


D-proline betaine

An amino acid betaine that is D-proline zwitterion in which both of the hydrogens attached to the nitrogen are replaced by methyl groups.


acetonitrile oxide

The nitrile oxide resulting from the oxidation of the nitrogen atom of acetonitrile.


An O-acylcarnitine that is carnitine having a 3-hydroxyicosadienoyl group as the acyl substituent (positions of the double bonds are unspecified).


O-propanoyl-L-carnitine

An optically active O-acylcarnitine compound having propanoyl as the acyl substituent and (R)-configuration at the 3-position.


O-glutaconylcarnitine

An O-acylcarnitine in which the acyl group specified is glutaconyl.


saturated fatty acyl-L-carnitine

An O-acylcarnitine in which the R is a saturated fatty acyl chain.


An O-acylcarnitine having 3-hydroxypalmitoleoyl as the acyl substituent.


nitrile sulfide

Members of the class of  nitrilium betaine that include compounds having the structure R-C#NS.


O-valeroylcarnitine

A C5-acylcarnitine in which the acyl group specified is valeroyl.


NSDB 211

An ammonium betaine derivative of propanesulfonic acid. One of a group of non-detergent sulfobetaines having a sulfobetaine hydrophilic group and a short hydrophobic group that cannot aggregate to form micelles.


octenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a octenoyl group as the acyl substituent in which the position of the double bond is unspecified.


O-nonanoylcarnitine

A C9-acylcarnitine having nonanoyl as the acyl substituent.


O-sebacoylcarnitine

An O-acylcarnitine having sebacoyl as the acyl substituent.


An O-acylcarnitine having (2E)-7-carboxyhept-2-enoyl as the acyl substituent.


An O-acylcarnitine having (9Z)-3-hydroxydodecenoyl as the acyl substituent.


O-propenoyl-D-carnitine

An O-acyl-L-carnitine in which the acyl group specified is propenoyl.


O-(hydroxyhexadecanoyl)carnitine

An O-acylcarnitine that is carnitine having a hydroxyhexadecanoyl group as the acyl substituent in which the position of the hydroxy group is unspecified.


O-tetradecenoylcarnitine

An  O-acylcarnitine in which the acyl group specified is tetradecenoyl.


CEFTAROLINE

A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil.  Used for the treatment of adults with acute bacterial skin and skin structure infections.


An O-acylcarnitine in which the O-acyl group is specified as (3R,11Z,14Z)-3-hydroxyicosadienoyl.


6-(methylthio)hexanonitrile oxide

A nitrile oxide that is pentane in which two of the terminal methyl hydrogens at positions 1 and 5 have been replaced by oxidonitrile and methylsulfanyl groups.


O-methylmalonyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is methylmalonyl.


An O-acyl-L-carnitine that is L-carnitine having a 3-methylglutaryl group as the acyl substituent


An O-acyl-L-carnitine in which the acyl group is specified as 3-hydroxyvaleryl.


acetyl-L-carnitine

An O-acyl-L-carnitine where the acyl group specified is acetyl. It facilitates movement of acetyl-CoA into the matrices of mammalian mitochondria during the oxidation of fatty acids.


fatty acylcarnitine

Any O-acylcarnitine in which the acyl group is a fatty acid and the carnitine component has configuration undefined.


O-pimeloylcarnitine

An O-acylcarnitine having pimeloyl as the acyl substituent.


An O-acyl-L-carnitine in which the acyl group is specified as 3-oxopalmitoyl.


O-adipoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is adipoyl.


An O-acylcarnitine having 3-hydroxybutyryl as the acyl substituent.


O-nonanoyl-L-carnitine

The L-enantiomer of  O-nonanoylcarnitine.


O-hydroxytetradecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxytetradecenoyl group as the acyl substituent in which the positions of the hydroxy group and the double bond are unspecified.


An O-hexadecenoylcarnitine having (2E)-hexadecenoyl as the acyl substituent.


O-(hydroxyvaleryl)carnitine

An O-acylcarnitine having hydroxyvaleryl as the acyl substituent in which the position of the hydroxy group is unspecified.


An O-acylcarnitine having 17-carboxyheptadecanoyl as the acyl substituent.


nitrilium betaine

Derivatives of nitriles having the general structure R-C#N(+)-Y(-). A subclass of 1,3-dipolar compounds including nitrile imides, nitrile oxides, nitrile sulfides and nitrile ylides.


O-propenoylcarnitine

An O-acyl carnitine in which the acyl group specified is propenoyl.


cis-4-hydroxy-D-proline betaine

An amino-acid betaine that is trans-4-hydroxy-D-proline zwitterion in which both of the hydrogens attached to the nitrogen have been replaced by methyl groups.


An O-acylcarnitine having (11Z)-eicoseneoyl as the acyl substituent.


An O-acyl-L-carnitine in which the acyl group is specified as 4,8-dimethylnonanoyl.


An O-methylglutarylcarnitine compound having 3-methylglutaryl as the acyl substituent.


An O-acylcarnitine having (9Z)-17-carboxyheptadec-9-enoyl as the acyl substituent.


An O-acylcarnitine having (2E)-hexenedioyl as the acyl substituent.


O-malonyl-D-carnitine

An O-acyl-D-carnitine in which the acyl group specified is malonyl.


An O-hydroxytetradecenoylcarnitine having (9Z)-3-hydroxytetradec-9-enoyl as the acyl substituent.


(R)-oleoylcarnitine

An O-acyl-L-carnitine in which the acyl group is specified as oleoyl.


An O-tetradecadienoylcarnitine  having (5Z,8Z)-tetradecadienoyl as the acyl substituent.


THIAMIN DIPHOSPHATE

An ammonium betaine that is the conjugate base of thiamine(1+) diphosphate arising from the deprotonation of one of the hydroxy groups of the terminal phosphate group.


S,S-dimethyl-beta-propiothetin

A sulfonium betaine obtained by deprotonation of the carboxy group of 3-dimethylsulfoniopropionic acid.


O-methylmalonylcarnitine

An O-acylcarnitine having methylmalonyl as the acyl substituent.


An O-acylcarnitine having (9Z)-3-hydroxyoctadecenoyl as the acyl substituent.


Any O-acylcarnitine in which the acyl group contains a total of 5 carbon atoms.


O-isobutyryl-L-carnitine

An optically active form of O-isobutyrylcarnitine having (R)-configuration.


O-pimelylcarnitine

An O-acylcarnitine in which the acyl group specified is pimelyl.


L-carnitine

The (R)-enantiomer of carnitine.


An O-acylcarnitine having 3-hydroxyhexadecanoyl as the acyl substituent.


O-(dimethylnonenoyl)carnitine

An O-acylcarnitine in which the acyl group is specified as dimethylnonenoyl (positions of double bond and methyl groups not specified).


O-octadecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a octadecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


O-propanoyl-D-carnitine

An O-acyl-D-carnitine in which  the acyl group specified is propanoyl.


O-palmitoleoylcarnitine

An O-acylcarnitine having palmitoleoyl as the acyl substituent.


O-malonylcarnitine

An O-acylcarnitine having malonyl as the acyl substituent.


diazonium betaine

An onium betaine having a diazonium as the positively charged component.


O-linoelaidylcarnitine

An O-octadecadienoylcarnitine having linoelaidyl as the acyl substituent.


O-lauroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as lauroyl (dodecanoyl).


Major species at pH 7.3


O-(hydroxytetradecadienoyl)-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxytetradecadienoyl group as the acyl substituent in which the positions of the two double bonds and the hydroxy group are unspecified.


O-hexenoylcarnitine

An O-acyl carnitine in which the acyl group specified is hexenoyl.


O-acylcarnitine

Any carboxylic ester obtained by the O-acylation of carnitine.


D-phenylalanine betaine

A D-phenylalanine derivative obtained by trimethylation of the amino function of D-phenylalanine.


polyunsaturated fatty acyl-L-carnitine

Any fatty acyl-L-carnitine where the fatty acid has 2 or more unsaturations. Major species at pH 7.3


O-hydroxyhexanoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexanoyl group as the acyl substituent in which the position of the hydroxy group is unspecified.


thiaminium carboxylate betaine

An ammonium betaine that is the conjugate base of thiamine(1+) carboxylic acid arising from the deprotonation of the carboxy group.


An O-acyl-D-carnitine in which the acyl group is specified as (11E)-octadecenoyl.


O-hexenoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is hexenoyl in which the position of the double bond is unspecified.


meldonium

An ammonium betaine that is beta-alaninate in which one of the amino hydrogens is replaced by a trimethylamino group. A clinically used cardioprotective drug that is used for treatment of heart failure, myocardial infarction, arrhythmia, atherosclerosis and diabetes.


A O-hydroxyhexadecenoyl-L-carnitine in which the acyl group specified is 3-hydroxy-(9Z)-hexadecenoyl.


O-tetradecadienoylcarnitine

An O-acylcarnitine in which the acyl group specified is tetradecadienoyl.


An O-acylcarnitine having 3-hydroxytetradecanoyl as the acyl substituent.


O-decadienoylcarnitine

An O-acylcarnitine in which the acyl group specified is decadienoyl in which the positions of the double bonds is unspecified..


O-hydroxybutyryl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxybutyryl group as the acyl substituent in which the positions of  the hydroxy group is unspecified.


A C5-acylcarnitine having 2-methylbutyryl as the acyl substituent.


amino-acid betaine

Any amino acid-derived zwitterion - such as glycine betaine (N,N,N-trimethylammonioacetate) - in which the ammonium nitrogen carries methyl substituents and bears no hydrogen atoms.


2,6-dimethylheptanoyl carnitine

A C9-acylcarnitine in which the acyl group specified is 2,6-dimethylheptanoyl.


O-valeroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is valeroyl.


fatty acyl-L-carnitine

Any O-acylcarnitine in which the carnitine component has L-configuration and the acyl group is a fatty acid.


An O-(hydroxytetradecadienoyl)carnitine having (5Z,8Z)-3-hydroxytetradecadienoyl as the acyl substituent.


An O-acylcarnitine having 3-hydroxydodecanoyl as the acyl substituent.


Cy3B dye NHS ester

A fluorescent dye with a maximum emission wavelength of 572 nm, derived from a heteroheptacyclic ring system.


lauryl sulfobetaine

An ammonium betaine in which the ammonium nitrogen is substituted by dodecyl, 3-sulfatopropyl and two methyl groups.


O-dodecenoylcarnitine

An O-acylcarnitine in which the acyl group specified is dodecenoyl.


O-glutaroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as glutaroyl.


An O-tetradecenoyl-L-carnitine in which the acyl group is specified as myristoleoyl.


O-butenoylcarnitine

An O-acyl carnitine in which the acyl group specified is butenoyl.


(R)-acetoacetylcarnitine

An O-acyl-L-carnitine in which the acyl group is specified as acetoacetyl.


O-methylglutarylcarnitine

An O-acylcarnitine in which the acyl group specified is methylglutaryl.


O-pimelyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a pimelyl group as the acyl substituent.


An amino-acid betaine obtained by deprotonation of the carboxy group of any N(5),N(5),N(5)-trimethyl-N(2)-[(3R)-3-(acyloxy)acyl]-L-ornithine; major species at pH 7.3.


S-methyl-L-ergothioneine

An amino acid betaine that is ergothioneine in which the hydrogen attached to the sulfur is replaced by a methyl group. It has been isolated from the deepwater (500-1,600 m) marine sponge Macandrewia azorica.


CARNITINE

An amino-acid betaine that is butanoate substituted with a hydroxy group at position C-3 and a trimethylammonium group at C-4.


O-(hydroxyoctadecenoyl)carnitine

An O-acylcarnitine having hydroxyoctadecenoyl as the acyl group in which the position of the double bond and hydroxy group are unspecified.


O-hexadecenedioylcarnitine

An O-acylcarnitine that is carnitine having a hexadecenedioyl group as the acyl substituent (position of the double bond is unspecified).


O-hexanoylcarnitine

An O-acylcarnitine compound having hexanoyl as the acyl substituent.


O-octadecadiendioylcarnitine

An O-acylcarnitine obtained by formal condensation of one of the carboxy groups of any  octadecadiendioic acid with the hydroxy group of carnitine.


An amino-acid betaine gamma-aminobutyric acid zwitterion in which all of the hydrogens attached to the nitrogen are replaced by methyl groups.


An O-acylcarnitine having (13Z,16Z)-docosadienoyl as the acyl substituent.


An O-acylcarnitine having (5Z)-tetradecenoyl as the acyl substituent.


An  octenoyl-Lcarnitine having 2-octenoyl as the acyl substituent.


methyl-branched fatty acyl-L-carnitine

An O-acylcarnitine in which the R group is a methyl-branched fatty acyl chain.


O-(hydroxypropionyl)carnitine

An O-acylcarnitine in which the acyl group specified is hydroxypropionyl.


NDSB 221

An ammonium betaine derivative of 3-(piperidin-1-yl)propane-1-sulfonic acid. One of a group of non-detergent sulfobetaines having a sulfobetaine hydrophilic group and a short hydrophobic group that cannot aggregate to form micelles.


Major species at pH 7.3


An O-acylcarnitine having (11Z,14Z)-eicosadienoyl as the acyl substituent.


An O-acylcarnitine having 3-hydroxylinoleoyl as the acyl substituent.


O-octanoyl-D-carnitine

An O-acyl-D-carnitine in which the acyl group specified as octanoyl.


O-malonyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as malonyl.


An O-acylcarnitine having 3-hydroxyeicosanoyl as the acyl substituent.


O-fumarylcarnitine

An O-acylcarnitine in which the acyl group specified is fumaryl.


O-hydroxyhexadecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexadecadienoyl group as the acyl substituent in which the positions of the two double bonds and the hydroxy group are unspecified.


An O-acylcarnitine having 3-hydroxyoctanoyl as the acyl substituent.


O-tetradecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having tetradecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


A non-proteinogenic dipeptide formed from L-gamma-glutamic acid and hercynyl-L-cysteine sulfoxide residues. It is an intermediate in the synthesis of ergothioneine, a compound found in certain fungi and mycobacteria.


O-tetradecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a tetradecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E)-docosapentaenoyl.


nitrile oxide

Compounds having the structure R-C#NO.


O-palmitoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as palmitoyl (hexadecanoyl).


O-icosanoylcarnitine

An O-acylcarnitine having icosanoyl (arachidoyl) as the acyl substituent.


O-dodecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having dodecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


TRIGONELLINE

An iminium betaine that is the conjugate base of N-methylnicotinic acid, arising from deprotonation of the carboxy group.


An O-(hydroxyhexadecadienoyl)carnitine having (9Z,12Z)-3-hydroxyhexadecadienoyl as the acyl substituent.


O-linoleoylcarnitine

An O-acylcarnitine having linoleoyl as the acyl substituent.


trans-4-hydroxy-L-proline betaine

An amino-acid betaine that is trans-4-hydroxy-L-proline zwitterion in which both of the hydrogens attached to the nitrogen have been replaced by methyl groups.


An O-acylcarnitine having 3-hydroxyarachidonoyl as the acyl substituent.


O-(hydroxytetradecadienoyl)carnitine

An O-acylcarnitine in which the acyl group specified is hydroxytetradecadienoyl.


An O-acylcarnitine having 3-hydroxyisovaleryl as the acyl substituent.


An O-acylcarnitine having 3-hydroxy-cis-5-octenoyl as the acyl substituent.


O-glutaconyl-L-carnitine

An O-acyl-L-carnitine where the acyl group specified is glutaconyl.


An O-acylcarnitine having (2E,5Z,7E)-decatrienoyl as the acyl substituent.


monounsaturated fatty acyl-L-carnitine

An O-acylcarnitine in which the R is a monounsaturated fatty acyl chain.


Major species at pH 7.3


O-nonadecanoylcarnitine

An O-acylcarnitine having nonadecanoyl as the acyl substituent.


fenmezoditiaz

An iminium betaine that is 2,3,7,8-tetrahydro[1,3]thiazolo[3,2-a]pyrimidin-4-ium substituted by a 2-chloro-1,3-thiazol-5-yl, oxidanidyl, phenyl, oxo, and methyl groups at positions 3R, 5, 6, 7 and 8, respectively. It is a mesoionic insecticide developed by BASF.


Published in DOI:10.1080/00021369.1989.10869245. Major species at pH 7.3.


O-dodecanoylcarnitine

An O-acylcarnitine having dodecanoyl as the acyl substituent.


serpentine

An indole alkaloid that is 18-oxayohimban dehydrogenated at positions 3, 4, 5, 6, 16 and 17 and substituted by a methyl group at the 19alpha position and by a methoxycarbonyl group at position 16.


O-decanoylcarnitine

An O-acylcarnitine compound having decanoyl as the acyl substituent.


O-acyl-D-carnitine

An O-acylcarnitine in which the carnitine component has D-configuration.


An O-acylcarnitine having (5Z)-13-carboxytridec-5-enoyl as the acyl substituent.


O-decanoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having decanoyl as the acyl substituent.


perifosine

A phospholipid consisting of 1,1-dimethylpiperidinium-4-yl hydrogen phosphate in which the hydrogen is replaced by a stearyl (octadecyl) group.


O-isovalerylcarnitine

A C5-acylcarnitine having isovaleryl as the acyl substituent.


An O-tetradecenoylcarnitine  having 2-tetradecenoyl as the acyl substituent.


An O-tetradecenoyl-L-carnitine obtained by formal condensation of the carboxy group of (5E)-tetradecenoic acid with the hydroxy group of L-carnitine.


L-proline betaine

An amino acid betaine that is L-proline zwitterion in which both of the hydrogens attached to the nitrogen are replaced by methyl groups.


An O-hydroxybutyryl-L-carnitine in which the acyl group is specified as 3-hydroxybutyryl.


O-pentadecanoylcarnitine

An O-acylcarnitine in which the acyl group is specified as pentadecanoyl.


Major species at pH 7.3


O-decenoylcarnitine

An O-acylcarnitine in which the acyl group is specified as decenoyl (position of double bond not specified).


O-(hydroxyhexadecanoyl)-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexadecanoyl group as the acyl substituent in which the position of the hydroxy group  is unspecified.


L-phenylalanine betaine

An L-phenylalanine derivative obtained by trimethylation of the amino function of L-phenylalanine.


O-butenoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is butenoyl in which the position of the double bond is unspecified.


A sulfonium betaine obtained by deprotonation of the carboxy groups and protonation of the amino group of S-adenosyl-S-carboxymethyl-L-homocysteine. Major microspecies at pH 7.3


choline sulfate

An ammonium betaine that is the conjugate base of choline hydrogen sulfate, obtained by deprotonation of the sulfate OH group.


thiamine(1+) triphosphate(1-)

An ammonium betaine that is the conjugate base of thiamine(1+) triphosphate arising from the deptoronation of one of the hydroxy groups of the terminal phosphate group.


O-oleoylcarnitine

An O-acylcarnitine having oleoyl as the acyl substituent.


Hypaphorine

An amino acid betaine obtaine by exhaustive methylation of the alpha-amino group of L-tryptophan with concomitant deprotonation of the carboxy group.


CYNOOXIDE ANION

A nitrile oxide resulting from the oxidation of hydrogen cyanide.


O-glutarylcarnitine

An O-acylcarnitine having glutaryl as the acyl substituent.


O-dodecanedioylcarnitine

An O-acylcarnitine having 11-carboxyundecanoyl as the acyl substituent.


O-hydroxyoctadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyoctadecenoyl group as the acyl substituent in which the position of the double bond and the hydroxy group is unspecified.


An optically active form of O-2-methylbutyrylcarnitine having (R)-configuration.


O-decenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having decenoyl group as the acyl substituent in which the position of the double bond is unspecified.


O-hexadecenoylcarnitine

An  O-acylcarnitine having a hexadecenoyl group with an unspecified double bond as the acyl substituent.


beta-alanine betaine

A beta-alanine derivative arising from quaternisation of the nitrogen of beta-alanine with three methyl groups and removal of the proton attached to the carboxy group. It is an osmoprotective compound accumulated by most members of the highly stress-tolerant Plumbaginaceae family.


D-CARNITINE

The (S)-enantiomer of carnitine.


O-octenedioylcarnitine

An O-acylcarnitine obtained by formal condensation of one of the carboxy groups of any octenedioic acid with the hydroxy group of carnitine.


nitrile ylide

A 1,3-dipolar compound having the structure: RC#N(+)-C(-)R2 <-> RC(-)=N(+)=CR2 <-> RC(+)=NC(-)R2 <-> R(.)C(.)-N=CR2.


D-tyrosine betaine

A D-tyrosine derivative obtained by trimethylation of the amino function of D-tyrosine.


5-hydroxyectoine zwitterion

An iminium betaine resulting from a transfer of a proton from the carboxy group to the imino group of 5-hydroxyectoine.  It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).


O-hexanoyl-L-carnitine

An O-hexanoylcarnitine that has L configuration.


O-adipoylcarnitine

An O-acylcarnitine compound having adipoyl as the acyl substituent.


An O-dodecenoylcarnitine having (5Z)-dodecenoyl as the acyl substituent.


O-hexadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hexadecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


O-stearoylcarnitine

An O-acylcarnitine having stearoyl (octadecanoyl) as the acyl substituent.


(S)-carnitinyl-CoA betaine

A 3-hydroxyacyl-CoA where the S-acyl group is specified as (S)-carnitinyl.


thiamine(1+) monophosphate(1-)

An ammonium betaine that is the conjugate base of thiamine(1+) monophosphate arising from the deprotonation of one of the phosphate hydroxy groups.


hydroxy-fatty acyl-L-carnitine

An O-acylcarnitine in which the R group is a hydroxylated fatty acyl chain.


An O-acylcarnitine having 11-carboxyundecanoyl as the acyl substituent.


O-(hydroxytetradecenoyl)carnitine

An O-acylcarnitine in which the acyl group specified is hydroxytetradecenoyl.


O-heptenoylcarnitine

An O-acylcarnitine that is the O-heptenoyl derivative of carnitine.


N-diazoacetylnorleucine methyl ester

A  diazonium betaine obtained by the deprotonation of the hydroxy group of (Z)-2-hydroxy-2-{[(2S)-1-methoxy-1-oxohexan-2-yl]amino}ethenediazonium.


O-octadecadienoylcarnitine

An O-acylcarnitine in which the acyl group specified is octadecadienoyl.


O-acyl-L-carnitine

An O-acylcarnitine in which the carnitine component has L-configuration.


(+)-(S)-alapyridaine

An iminium betaine that is L-alanine in which the amino group is replaced by a 5-hydroxy-2-(hydroxymethyl)pyridinium-1-yl moiety.


O-heptanoylcarnitine

An  O-acylcarnitine that is the O-heptanoyl derivative of carnitine.


tyrosine betaine

An amino acid betaine derived from tyrosine.


O-heptadecanoylcarnitine

An O-acylcarnitine in which the acyl group is specified as heptadecanoyl.


oxo-fatty acyl-L-carnitine

An O-acyl-L-carnitine obtained by formal condensation of the carboxy group of any oxo-fatty acid with the hydroxy group of L-carnitine.


O-hexadecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hexadecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


An O-decenoylcarnitine having (4Z)-decenoyl as the acyl substituent.


O-undecenoylcarnitine

An O-acylcarnitine in which the acyl group is specified as undecenoyl (position of double bond not specified).


lauramidopropyl betaine

An ammonium betaine in which the the ammonium nitrogen is substituted by two methyl groups and a lauramidopropyl group.  It is the major (>50%) component of cocamidopropyl betaine.


phenylalanine betaine

An amino acid betaine derived from phenylalanine.


An O-acylcarnitine having (2E)-octenoyl as the acyl substituent.


An O-acylcarnitine having (9Z,12Z,15Z)-3-hydroxyoctadecatrienoyl as the acyl substituent.


O-octanoylcarnitine

An O-acylcarnitine having octanoyl as the acyl substituent.


O-octenoylcarnitine

An O-acylcarnitine in which the acyl group specified is octenoyl.


An O-octadecenoylcarnitine in which the acyl group is specified as (9E)-octadec-9-enoyl.


An O-acylcarnitine having 15-carboxypentadecanoyl as the acyl substituent.


nitrile selenide

Members of the class of nitrilium betaine that are compounds having the structure R-C#NSe.


O-hydroxypropionyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is hydroxypropionyl in which the position of the hydroxy group is unspecified..


O-tiglyl-L-carnitine

An O-acyl-L-carnitine compound having trans-2-methyl-2-butenoyl (tiglyl) as the acyl substituent.


An O-acylcarnitine having 3-hydroxydecanoyl as the acyl substituent.


O-decadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having decadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


A non-proteinogenic dipeptide formed from L-gamma-glutamic acid and hercynyl-L-selenocysteine residues.


O-dodecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a dodecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


An N-glycosylpyridine that is the N-alpha-D-glucosiduronyl derivative of (S)-nicotine.


(R)-icosanoylcarnitine

An O-acyl-L-carnitine in which the acyl group is specified as icosanoyl.


An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E,19E)-docosahexaenoyl.


Any O-acylcarnitine in which the acyl group contains a total of 4 carbon atoms.


O-isobutyrylcarnitine

An O-acylcarnitine having isobutyryl as the acyl substituent.


sulfonium betaine

Neutral molecules having charge-separated forms with an sulfonium atom which bears no hydrogen atoms and that is not adjacent to the anionic atom.


O-tiglylcarnitine

An O-acylcarnitine compound having trans-2-methyl-2-butenoyl (tiglyl) as the acyl substituent.


An O-acylcarnitine having (7Z,10Z,13Z,16Z)-docosatetraenoyl as the acyl substituent.


O-butanoyl-L-carnitine

An optically active form of O-butanoylcarnitine having L-configuration.


Major species at pH 7.3.


O-octadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a octadecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


ceftaroline fosamil

A cephalosporin having [4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl and {(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino side groups located at positions 3 and 7 respectively. The N-phospho prodrug of ceftaroline, a broad-spectrum antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA). It is used for the treatment of adults with acute bacterial skin and skin structure infections.


O-pivaloylcarnitine

A C5-acylcarnitine in which the acyl group specified is pivaloyl.


O-behenoylcarnitine

An O-acylcarnitine having behenoyl (docosanoyl) as the acyl substituent.


7-(methylthio)heptanonitrile oxide

A nitrile oxide that is hexane in which two of the terminal methyl hydrogens at positions 1 and 6 have been replaced by oxidonitrile and methylsulfanyl groups.


An O-acylcarnitine in which the acyl group is specified as 2-octadecenoyl.


S-methyl-L-methioninate

A sulfonium betaine that is a conjugate base of S-methyl-L-methionine obtained by the deprotonation of the carboxy group.


O-fumaryl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as fumaryl.


O-octadecenoylcarnitine

An  O-acylcarnitine in which the acyl group specified is octadecenoyl.


O-(hydroxyhexadecenoyl)carnitine

An O-acylcarnitine having a hydroxyhexadecenoyl group as the acyl substituent in which the position of the hydroxy group and the double bond is unspecified.


O-tetradecanoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as myristoyl (tetradecanoyl).


ammonium betaine

Any neutral molecule having charge-separated forms with a quaternary ammonium atom which bears no hydrogen atoms and that is not adjacent to the anionic atom.


O-tetradecanoylcarnitine

An O-acylcarnitine having tetradecanoyl (myristoyl) as the acyl substituent.


Any O-acylcarnitine in which the acyl group contains a total of 9 carbon atoms.


Butyryl-carnitine

A C4-acylcarnitine  that is the O-butanoyl derivative of carnitine.


isovaleryl-L-carnitine

An O-isovalerylcarnitine that is the 3-methylbutanoyl (isovaleryl) derivative of L-carnitine.


O-suberoylcarnitine

An O-acylcarnitine having suberoyl (7-carboxyheptanoyl) as the acyl substituent.


O-hydroxyhexadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexadecenoyl group as the acyl substituent in which the position of the hydroxy group and the double bond is unspecified.


O-octadecanoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as stearoyl (octadecanoyl).


L-tyrosine betaine

An L-tyrosine derivative obtained by trimethylation of the amino function of L-tyrosine.


O-octanoyl-L-carnitine

The L-enantiomer of an O-octanoylcarnitine.


Palmitoyl-carnitine

An O-acylcarnitine having palmitoyl (hexadecanoyl) as the acyl substituent.


An optically active form of 2,6-dimethylheptanoylcarnitine having (R)-configuration.


An O-acylcarnitine having 3-hydroxyoctadecanoyl as the acyl substituent.


An O-acylcarnitine having (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl as the acyl substituent.


An ammonium betaine that is the conjugate base of 3-dehydrocarnitinium; major species at pH 7.3.


N-acetyl-alpha-D-muramoyl-L-alanine

A glyco-amino acid compound consisting of an N-acetyl-alpha-D-muramoyl group attached to L-alanine via an amide linkage.


GUANAZOLE

An aromatic amine that is 1,2,4-triazole substituted at positions 3 and 5 by amino groups.


VARESPLADIB METHYL

A methyl ester resulting from the formal condensation of the carboxy group of varespladib with methanol. It is a potential therapy for the treatment of snakebite envenomings in which toxicity depends on the action of PLA2s.


An N-propionylated alpha-(2->8)-linked homosialopolysaccharide consisting of five alpha-D-N-propionylneuraminyl residues joined by (2->8) linkages (i.e. [8)-alpha-Neu5Pr-(2->]n  where n = 5).


A long-chain fatty alcohol that is tetradecan-1-ol bearing a methyl substituent at position 13.


name: Stage IA Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: pT1, N0, M0, S0. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Immature Teratoma

description: An immature teratoma occurring in children.


name: Localized Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Tumor confined to the testes. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Choriocarcinoma

description: A choriocarcinoma occurring in children.


name: Stage III Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, Any N, M1, SX. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Testicular Yolk Sac Tumor, Prepubertal-Type

description: Testicular yolk sac tumor that almost always occurs in pure form and is not associated with germ cell neoplasia in situ. It affects young children and is the most frequently seen testicular neoplasm in prepubertal children.


Childhood Mature Teratoma

description: A mature teratoma occurring in children.


name: Refractory Childhood Malignant Germ Cell Tumor

description: A malignant germ cell tumor that occurs during childhood and is resistant to treatment.


name: Stage IIIC Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1-N3, M0, S3 or Any pT, Any N, M1, S3. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage IIIB Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1-N3, M0, S2 or Any pT, Any N, M1, S2. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Childhood Malignant Testicular Germ Cell Tumor

description: A malignant germ cell tumor in children arising from the testis.  It includes the embryonal carcinoma, yolk sac tumor, choriocarcinoma, and mixed germ cell tumors.


name: Recurrent Childhood Malignant Germ Cell Tumor

description: The reemergence of a malignant germ cell tumor in children after a period of remission.


name: Stage IB Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: pT2-4, N0, M0, S0. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Germinomatous Germ Cell Tumor

description: A germinomatous germ cell tumor occurring in children.


Childhood Mixed Germ Cell Tumor

description: A mixed germ cell tumor occurring in children.


name: Stage IIA Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1, M0, S0, S1. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage II Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1-3, M0, SX. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Extracranial Germ Cell Tumor

description: A childhood benign or malignant germ cell tumor arising from an anatomic site other than the brain.


name: Metastatic Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Distant metastases present. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Teratoma

description: A mature or immature teratoma occurring in children.


Childhood Seminoma

description: A seminoma occurring in children.


Childhood Embryonal Carcinoma

description: An embryonal carcinoma occurring in children.


Childhood Extragonadal Teratoma

description: An extragonadal teratoma that occurs during childhood.


name: Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2 Stage, Tier 2

description: A term that refers to the staging of childhood testicular germ cell tumor according to the tier 2 Toronto childhood cancer staging guidelines v2.


name: Regional Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Tumor extension to regional lymph nodes: interaortocaval, para-aortic (periaortic), paracaval, preaortic, precaval, retroaortic, retrocaval, and along spermatic cord. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage IIB Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N2, M0, S0, S1. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Childhood Extragonadal Malignant Germ Cell Tumor

description: A malignant germ cell tumor in children arising from an anatomic site other than the testis or ovary.


name: Childhood Central Nervous System Teratoma

description: A mature or immature teratoma affecting the central nervous system and occurring in children.


Childhood Benign Germ Cell Tumor

description: A germ cell tumor that occurs during childhood and is characterized by the absence of atypia and metastatic potential.


name: Childhood Nongerminomatous Germ Cell Tumor

description: A nongerminomatous germ cell tumor occurring in children.


name: Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2 Stage, Tier 1

description: A term that refers to the staging of childhood testicular germ cell tumor according to the tier 1 Toronto childhood cancer staging guidelines v2.


name: Childhood Testicular Non-Seminomatous Germ Cell Tumor

description: A non-seminomatous germ cell tumor that arises in the testis and occurs in children.


name: Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2 Stage

description: A term that refers to the staging of childhood testicular germ cell tumor according to the Toronto childhood cancer staging guidelines v2.


name: Stage IS Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N0, M0, S1-3. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage I Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: pT1-4, N0, M0, SX. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage IIC Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N3, M0, S0, S1. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Testicular Yolk Sac Tumor

description: A yolk sac tumor that arises from the testis during childhood.


A galactosiduronic acid in which beta-D-galacturonic acid is linked glycosidically to a 3-aminopropyl group.


HOMOSERINE LACTONE

The L-enantiomer of homoserine lactone.


name: Quercetin 5,7,3',4'-tetramethyl ether 3-galactoside


The (R)-enantiomer of 2-benzylsuccinyl-CoA.


omega-carboxyacyl-CoA

An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of any alpha,omega-dicarboxylic acid.


succinyl-CoA

An omega-carboxyacyl-CoA having succinoyl as the S-acyl component.


A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxypimelic acid.


An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-benzylsuccinic acid.


pimeloyl-CoA

An omega carboxyacyl-CoA that is the S-pimeloyl derivative of coenzyme A.


oxalyl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of oxalic acid.


mesaconyl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the 1-carboxy group of mesaconic acid.


(R)-ethylmalonyl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of (R)-ethylmalonic acid.


An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the least hindered carboxy group of mesaconic acid.